Yayın:
Antitumor Effects of Dihydromyricetin and Bevacizumab on SKOV-3 Ovarian Cancer Cell Line

Sadeleştirilmiş öğe sayfası
dc.contributor.authorProfessor, Ayşe Tansu Koparal
dc.contributor.authorHulusi Göktuğ Gürer
dc.contributor.authorCeren Yıldız Eren
dc.contributor.authorAyşe Tansu Koparal Professor
dc.contributor.authorSinem Dabağoğlu
dc.contributor.orcid0000-0001-8821-9469
dc.contributor.orcid0000-0003-1648-3345
dc.date.accessioned2025-11-13T19:41:03Z
dc.date.issued2022-07-07
dc.identifier.doihttps://doi.org/10.5281/zenodo.6808034
dc.identifier.openalexW4284887471
dc.identifier.urihttps://hdl.handle.net/11421/11563
dc.identifier.urihttps://doi.org/10.5281/zenodo.6808034
dc.language.isoen
dc.relation.ispartofZenodo (CERN European Organization for Nuclear Research)
dc.rightsopenAccess
dc.subjectBevacizumab
dc.subjectOvarian cancer
dc.subjectCancer research
dc.subjectOncology
dc.subjectInternal medicine
dc.subjectMedicine
dc.subjectCancer
dc.subjectChemotherapy
dc.subject.sdg3
dc.titleAntitumor Effects of Dihydromyricetin and Bevacizumab on SKOV-3 Ovarian Cancer Cell Line
dc.typeArticle
dspace.entity.typePublication
local.authorid.openalexA5056769708

Dosyalar

Koleksiyonlar

Publications